CN1912106A - Dysentery multivalent genetic engineering vaccine and preparation method thereof - Google Patents

Dysentery multivalent genetic engineering vaccine and preparation method thereof Download PDF

Info

Publication number
CN1912106A
CN1912106A CNA2005100898519A CN200510089851A CN1912106A CN 1912106 A CN1912106 A CN 1912106A CN A2005100898519 A CNA2005100898519 A CN A2005100898519A CN 200510089851 A CN200510089851 A CN 200510089851A CN 1912106 A CN1912106 A CN 1912106A
Authority
CN
China
Prior art keywords
dysentery
leu
ser
genetic engineering
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005100898519A
Other languages
Chinese (zh)
Inventor
王希良
邢丽
罗德炎
张松乐
王栋
江海燕
杨海荣
张良艳
高杰英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Microbiology and Epidemiology of AMMS
Original Assignee
Institute of Microbiology and Epidemiology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Microbiology and Epidemiology of AMMS filed Critical Institute of Microbiology and Epidemiology of AMMS
Priority to CNA2005100898519A priority Critical patent/CN1912106A/en
Publication of CN1912106A publication Critical patent/CN1912106A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses dysentery polyvalence gene engineering vaccine. Its active constituent can express not only affecting albumen antigen IpaA, IpaB, IpaC, IpaD, but also fushi and songneishi double-valence LPS-O polysaccharide antigen. Its advantages are that it has good polyvalence immunogenicity to protect immunized mouse and monkey, resist S.F2a and S.sonnei; it can reduce immunizing dose, offer polyvalence protection to effectively defend bacillary dysentery; and it can be produced in large scale.

Description

A kind of dysentery multivalent genetic engineering vaccine and preparation method thereof
Technical field
The present invention relates to a kind of dysentery multivalent genetic engineering vaccine and preparation method thereof in the field of biological pharmacy.
Background technology
Whole world dysentery year, morbidity example surpassed 2.5 hundred million, and wherein 5,000,000 examples need hospital care, and is year dead about 2,000,000, and the report data surplus in the of ten year is growing on and on.Mainly be popular in developing country.Dysentery is common and multiple transmissible disease, and sickness rate is positioned at preceding 3 of 24 kinds of Notifiable diseases all the time, and downtrending is year by year arranged, and at present the annual report case is about about 1,000,000, and the actual case number surpasses several times.Morbidity is based on infant and person between twenty and fifty, and old man and children are more common in death, and main popular type is Fu Shi and Song Nei Shi.Though dysentery has pharmacological agent, very easily transfer to chronicly, carrying disease germs for a long time becomes potential contagium, and the resistance problem is very serious.The oral rehydration that WHO recommends is to being that the dysentery of main pathogenic characteristic is invalid with the invasion and attack intestinal epithelial cell, especially because of influence of dysentery diarrhoea and obstacle infant normal development, influence throughout one's life, and more and more evidences illustrates that dysentery infection is relevant with autoimmune disease.Especially in recent years, China urban floating population increases severely, and is engaged in food and the processing number increases, and this part people's inhabitation and work under bad environment, all to the propagation of dysentery and popularly provide control environment, popular approach and responsive crowd.
Shigella (Shigella) is a class gram negative bacillus, is human bacillary dysentery common pathogenic bacteria the most, the common name dysentery bacterium.K and O antigen are arranged and do not have H antigen.K antigen is the somatic surface antigen from new isolating some bacterial strain of patient, and is thermo-labile, heat 100 ℃ 1 hour destroyed.K antigen is meaningless on serological typing, but can stop O antigen and corresponding sero-fast agglutination reaction.O antigen is divided into group specific antigen and type specific antigen, and the former is everlasting and occurs between several proximate bacterial classifications; The specificity height of type specific antigen is used to distinguish bacterial type.According to the difference of Shigellae antigen construct, can be divided into 48 serotypes of four group (comprising hypotype):
(1) A group: claim shigella dysenteriae (Sh.dysenteriae) again, the common name dysentery bacterium.Nonfermented N.F,USP MANNITOL.12 serotypes are arranged, and wherein 8 types are divided into three hypotypes again.
(2) B group: claim shigella flexneri (Sh.flexneri) again, the common name shigella flexneri.Fermentation N.F,USP MANNITOL.15 serotypes (containing hypotype and mutation) are arranged, and the antigen construct complexity has group antigen and type antigen.According to the antigenic difference of type, be divided into 6 types, the difference according to group antigen is divided into hypotype with type again; X, Y mutation do not have specific antigens, and different group antigens is only arranged.
(3) C group: claim Shigella bogdii (Sh.boydii) again, common name Bao Shi dysentery bacterium.Fermentation N.F,USP MANNITOL has 18 serotypes, various no cross reaction.
(4) D group: claim bacillus ceylonensis A (Sh.sonnei) again, the common name sonne bacillus.Fermentation N.F,USP MANNITOL, and delayed reaction lactose generally need 3~4 days.Has only a serotype.Two variation phases are arranged, promptly I mutually with II mutually; I is the S type mutually, and II is the R type mutually.
Invasin protein antigen (Ipas), be the common invasin protein antigen (Ipas of each group dysentery bacterium, comprise IpaA, IpaB, IpaC, IpaD), IpaA, IpaB, IpaC, IpaD are the protein that has amino acid residue sequence shown in (1,2,3 and 4) in the sequence table respectively, and their encoding gene is respectively shown in sequence in the sequence table (5,6,7 and 8).
The LPS-O polysaccharide antigen, the outside that promptly is present in dysentery bacterium muramyl peptide glycan is the structure of adventitia.It is the same with most of Gram-negative bacterias, and mainly by lipoid A, core polysaccharide and O-specific side chains (O antigen) are formed, and with intestinal bacteria very big similarity are arranged.Chemical analysis shows that the lipoid A of Salmonella LPS is identical with bacillus coli gene in Fu Shi and the Song, and the O specific side chains of LPS is the main position of decision serotype, is the important pathogenic factor and protective antigen of dysentery bacterium.
Countries such as U.S., method, day, Australia, Sweden, English, Soviet Union, India drop into a large amount of manpowers for a long time, financial resources are carried out shigella vaccine and corresponding fundamental research thereof, and dysentery bacterium virulence and morbific recent advances in research of molecular mechanism have promoted the development and the development of shigella vaccine of new generation.The method and the approach of development dysentery bacterium seedling mainly contain at present:
1, make up hybrid strain: how with Salmonellas such as Ty21a, or the E.coli bacterium is the acceptor strain, accepts the hybrid strain that Song Nei Shi or Fu Shi 2a dysentery bacillus plasmid or chromosomal function fragment make up.As in Song-the Ty21a hybrid strain, human body oral 10 10Cfu safety; attack to Song Nei Shi wild strain has 40% protection effect, but between its freeze-drying prods batch fluctuation is arranged, its reason be Song Nei Shi LPS-O side chain can not with the cause of the LPS center sugar chain stable bond of Ty21a; improve, but do not see the report of success.
2, make up the virulence gene attenuation mutant: be primarily aimed at the functional gene of sending out inside and outside dysentery bacillus breeding and the born of the same parents such as the gene of the arobactin on VirG (icsA) and regulatory gene or the karyomit(e), insert sudden change, make this bacterial strain can invade host cell, but can't effectively breed, on animalcule and monkey body, experimentize and do not seen the anthroposcopy effect.
3, make up the auxotroph of dysentery bacillus strain: make Y type dysentery bacillus because aroD gene disruption or disappearance, obtain Fu Shi dysentery attenuated strain, it can invade host cell, but can not effectively breed in born of the same parents, there are 2 strains to carry out volunteer's experiment, do not test on a large scale but be embedded in human body.
Above-mentioned three class vaccines have the human immunology observes except that 2 strain aroD auxotrophy bacterial strains, and other does not see the report of human body II, III phase clinical observation result.Carry out the aroD disappearance and the 2 strain attenuated strains that successfully construct carry out tens routine volunteer's safety respectively and attack experiment from F2a2457 strain and Fu Shi Y type, think oral 10 * 10 8Cfu is safer, and the experimenter 44% finds positive serum antibody, and side reaction is relevant with clothes seedling dosage, it is said that Y type attenuated strain Δ aroD124 is effectively on-the-spot in Vietnam.
4, the U.S. carries out crosslinked being called with dysentery bacillus LPS polysaccharide and albumen such as CT-B and combines seedling in recent years, and it is effective to carry out the animalcule experimental observation, observes also effectively at the on-the-spot human of Vietnam, but does not form goods.
Obtain national a kind new medicine certificate in 1998 and produce the dysentery bivalent gene engineering vaccine (bacterial strain FSM2117) of criticizing code; can express the two valency LPS-O polysaccharide antigens of Fu Shi and Song Nei Shi simultaneously; through different animals models such as mouse, cavy, rabbit and monkey proof dysentery bivalent gene engineering vaccine oral immunity animal safety, two valency immunogenicities, two valency protection activity and stable are arranged.And the on-the-spot on a large scale use of the crowd that is further used for, the oral dysentery bivalent gene engineering vaccine of reference safety has two valency immunogenicities and immune protective effect.And obtain national 1 class new biological product certificate and country trial production code in December, 1998.But before this dysentery bivalent gene engineering vaccine lyophilisate is oral earlier in the oral sodium bicarbonate and hydrochloric acid in gastric juice, and oral dose reaches the very good not enough problem of protection effect greatly, and influences immune protective effect.
The innovation and creation content
The purpose of this invention is to provide a kind of dysentery multivalent genetic engineering vaccine.
Dysentery multivalent genetic engineering vaccine provided by the present invention, its activeconstituents are both to have expressed invasin protein antigen I paA, IpaB, and IpaC and IpaD express the dysentery multivalent genetic engineering vaccine strain of the two valency LPS-O polysaccharide antigens of Fu Shi and Song Nei Shi again.
The production substratum of described dysentery multivalent genetic engineering vaccine is that pH is Hou Shi substratum or the LB substratum of 6.5-7.6.The pH of described production substratum is preferably 7.2-7.5.
Described Hou Shi substratum is prepared as follows: fresh beef 7500g adds 11250ml distilled water and boils 40min, be cooled to 45 ℃ of fresh pig pancreas 1500mg that add homogenate, transfer pH8.0, and adding trichloromethane 200ml, digestion 7d, with preceding 4 times of dilutions, and add sodium-chlor 0.5%, transfer pH6.5-7.6 standby.
The LB substratum is grouped into by following one-tenth: peptone 10g, yeast leach liquor 5g, sodium-chlor 10g, add water to 1000ml, and wherein the pH of institute is preferably 7.2-7.5.
The formulation of described dysentery multivalent genetic engineering vaccine is two kinds of oral capsule formulation or form of nose drops.
The dysentery multivalent genetic engineering vaccine of described formulation can adopt lyophilization to be prepared.
The lyophilized vaccine that is adopted in the dysentery multivalent genetic engineering vaccine process of the described formulation of preparation is for containing 0.5% gelatin, the pH7.0-7.6 phosphoric acid buffer of 5% sucrose, 0.1% vitamins C, 0.1% thiaminogen, 0.1% skim-milk etc.; Described percentage composition is the quality percentage composition.
Second purpose of the present invention provides a kind of method for preparing above-mentioned dysentery multivalent genetic engineering vaccine strain.
The method of the above-mentioned dysentery multivalent genetic engineering vaccine strain of preparation provided by the present invention may further comprise the steps:
1) will contain invasin protein IpaA, IpaB, the I of IpaC and IpaD gene plasmid mutually transfer among the shigella flexneri 2a type II, obtain containing the reorganization shigella flexneri 2a type II of described I phase plasmid;
2) will contain aroD genetically deficient among the reorganization shigella flexneri 2a type II of described I phase plasmid, both expressed invasin protein antigen I paA, IpaB, IpaC and IpaD express the dysentery multivalent genetic engineering vaccine strain of the two valency LPS-O polysaccharide antigens of Fu Shi and Song Nei Shi again.
The described invasin protein IpaA that contains, IpaB, the I of IpaC and IpaD gene plasmid mutually comes from Song Nei Shi dysentery bacterial strains such as Song Nei Shi dysentery bacillus strain 48025-11 or S63.This strain provides the I of 120-140MD mutually big plasmid, and invasin protein and invasion and attack phenotype are all positive (to have four kinds of invasin protein IpaA, IpaB, IpaC and IpaD, the Hela cell is invaded positive, the contact hemolysis positive, the Congo red test positive, binding film test in cavy angle is positive).
The described invasin protein IpaA that contains, IpaB, the I of IpaC and IpaD gene plasmid mutually transfer among the shigella flexneri 2a type II by luring kinoplaszm grain R386.
The described kinoplaszm grain R386 that lures comes from E.coli.This bacterial strain of E.coli provides and lures kinoplaszm grain R386 and selected marker Kan (kantlex) resistance.
Described shigella flexneri 2a type II can be shigella flexneri 2a type II T32 bacterial strain.
Dysentery multivalent genetic engineering vaccine of the present invention has increased the total invasin protein antigen (Ipas comprises IpaA, IpaB, IpaC, IpaD) of each group dysentery bacterium than dysentery bivalent gene engineering vaccine.Oral or the collunarium approach immunity through different experiments animal (mouse and monkey); result's proof is by the 0th; 3; 6 Wednesdays time oral or collunarium immune programme for children; mouse oral 0.1 hundred million; rhesus monkey oral 0.5 hundred million; human oral 1.0 hundred million or mouse collunarium 0.001 hundred million; rhesus monkey collunarium 0.005 hundred million; the dysentery multivalent genetic engineering vaccine of people's collunarium 0.01 hundred million; can produce good multivalent immunogenic; can protect immune mouse; rhesus monkey; the people effectively resists the attack of S.F2a and S.sonnei strain; and the oral route immune protective effect than dysentery bivalent gene engineering vaccine improves nearly 30%; collunarium approach immune protective effect improves more than 30%; can both effectively induce the two valency specific IgA of mucous membrane; the antibody response of IgG excrement and saliva; the immunoprotection of dysentery bacterium polyvalent antigen can be provided; and carry out pilot scale production and in 5 provinces; the city; people's on-site assessment surplus the area 30,000 can fine effective prevention bacillary dysentery.
Description of drawings
Fig. 1 is the building process synoptic diagram of dysentery multivalent genetic engineering vaccine strain of the present invention
Embodiment
Experimental technique among the following embodiment if no special instructions, is ordinary method.
Percentage composition among the following embodiment if no special instructions, is the quality percentage composition.
Embodiment 1. dysentery multivalent genetic engineering vaccine strains make up, screen and identify
1, the structure of dysentery multivalent genetic engineering vaccine strain and screening
(1) structure of dysentery multivalent genetic engineering vaccine strain
The building process of dysentery multivalent genetic engineering vaccine strain as shown in Figure 1, concrete grammar is as follows:
Select Song Nei Shi dysentery bacillus strain 48025-11 (to purchase in Inst. of Epidemiology and Microbiology, Academy of Military Medical Sciences, PL seed culture of viruses storehouse, provide the mutually big plasmid pSS120 of I of 120-140MD), express the IpaA relevant with invasion and attack, B, C, four invasin protein bands of D have the HeLa cell and invade, Congo red test, the invasion and attack phenotype such as contact hemolysis and the cavy angle binding film virulence test positive.Intestinal bacteria E.coli (R386::Tn5, Kan r25ug/ml purchases in capital children's hospital), the selected marker that lures kinoplaszm grain R386 and screening kalamycin resistance is provided.At first will lure kinoplaszm grain R386 to forward among the dysentery bacillus strain 48025-11 by the method for conjugal transfer, concrete grammar is as follows: the intestinal bacteria E.coli that providing of getting that glycerin bouillon preserves lures kinoplaszm grain R386 and each 50 μ 1 of dysentery bacillus strain 48025-11 are inoculated in respectively and contain and do not contain in the 5ml LB meat soup of kantlex, 37 ℃ of shaking culture 15 hours, centrifugal 10 minutes of 7000rpm, remove supernatant, lawn suspends with 0.2ml LB meat soup respectively, two bacterium are applied to the LB flat board after mixing, include Kan (kantlex) 50ug/ml, 37 ℃ of incubators were cultivated 30 hours, grow bacterium colony and dysentery Song Nei Shi standard serum is positive, continuously containing on the LB flat board of kantlex purifying 3 times, the gained bacterium colony is both for containing the dysentery bacillus strain 48025-11 that lures kinoplaszm grain R386.
By luring luring of kinoplaszm grain R386, the mutually big plasmid of I is transferred to Fu Shi 2a shigella vaccine T32 (expression type II, group 3,4 antigen Str (Streptomycin sulphate) r50ug/ml, Ipa-purchases in Lanzhou Institute of Biological Products) in, concrete grammar is as follows: the 48025-11 that glycerin bouillon is preserved (contains the mutually big plasmid of I and lures kinoplaszm grain R386Kan r) and Fu Shi 2a shigella vaccine T32 (Str r) respectively get 50 μ l and be inoculated in respectively and contain Kan (kantlex) 50ug/ml and containing in the 5ml LB meat soup of Str (Streptomycin sulphate) 50ug/ml, 37 ℃ of shaking culture 15 hours, 7000rpm removed supernatant in centrifugal 10 minutes, lawn suspends with 0.2ml LB meat soup respectively, two bacterium are applied to the LB flat board after mixing, include Kan (kantlex) 50ug/ml, Streptomycin sulphate 50ug/ml, 37 ℃ of incubators were cultivated 30 hours, grow bacterium colony and dysentery Song Nei Shi and Fu Shi 2a type II and group 3,4 standard serums are positive, continuously containing on the LB flat board of kantlex and Streptomycin sulphate purifying 3 times, the gained bacterium colony both had been the purpose bacterium colony, and this purpose bacterium colony is the Fu Shi 2a shigella vaccine T32 that changes the mutually big plasmid of I over to, called after FS-15 strain.The FS-15 strain is expressed Song's Nei Shi I phase antigen and Fu Shi 2a type II, group's 3,4 antigens, and express the IpaA relevant with invasion and attack, B, C, four invasin protein bands of D, have the intrusion of HeLa cell, the Congo red test positive, invasion and attack such as contact hemolysis phenotype, the cavy angle binding film virulence test positive.
(purchase the Research in Walter Reed Army Institute of, America contains the P1 phage, Kan with intestinal bacteria NK5131 r50ug/ml, Tet r12.5ug/ml Tn10 inserts the aroD gene of deactivation) preparation P1 lysate, tiring needs greater than 10 10Can use, mix with P1 lysate and FS-15 strain bacterium liquid, mode by transduction changes the aroD gene in the recipient bacterium over to, concrete grammar is as follows: the FS-1550 μ l that glycerin bouillon is preserved is inoculated in 5ml and contains in the LB meat soup of Kan50ug/ml, 37 ℃ shaking culture 8-9 hour, its whole transferred speciess are contained in the LB meat soup of Kan 50ug/ml in 200ml, it is centrifugal to get 60ml bacterium liquid, centrifugal 10 minutes of 4000rpm is suspended from 40mlCa, Mg damping fluid (5mM Cacl 2, 10mM MgSO 4) in, 37 ℃ of water-baths 30 minutes.Every 2ml bacterium liquid adds 2ml P1 lysate, and 37 ℃ adsorbed centrifugal 10 minutes of 4000rpm 30 minutes, every pipe is suspended from the 0.5ml LB meat soup, be laid on 3 LB flat boards that contain 50ug/ml kantlex and 12.5ug/ml Tet (tsiklomitsin), cultivated 55 hours for 42 ℃, have transduttant to occur.Continuous purifying 3 times on the flat board that contains kan 50ug/ml and Tet 12.5ug/ml.The transduttant dibbling on the M9 flat board that adds and do not add die aromatischen Aminosaeuren, is selected the bacterium colony of die aromatischen Aminosaeuren defective and preserved.Pass through Bochner substratum (peptone 10 grams, yeast 5 grams, 50 milligrams of duomycin .HCl, NaCl 10 grams, NaH again 2PO 411.3 gram, agar 15 grams, water 1000ml, PH6.0-6.5), screening sensitive tetracycline mutant.Again with sensitive tetracycline strain dibbling on the NC film, after the cracking with a- 32The aroD probe of the 1.0Kb of P mark is done bacterium colony in situ hybridization, and (conventional alkaline denaturation extracts the pKD201 plasmid and (purchases the HarborLaboratory in Cold Spring, America), with ClaI and EcoRV double digestion, reclaim the 1.0kb fragment, this fragment of random primering mark is as the aroD probe, colony hybridization method carries out routinely), the person of being negative is the aroD gene-deleted strain.The aroD gene-deleted strain is being contained nad (nicotinamide), VitB1 (VITMAIN B1), asp (aspartic acid), phe (phenylalanine), try (tryptophane), tyr (tyrosine), PABA (para-amino benzoic acid), make the auxotrophy of die aromatischen Aminosaeuren on the M9 substratum of DHB (2.3-resorcylic acid) (being 40ug/ml) and identify, and with NK5131 as positive control, filter out the bacterial strain (FS) that 4 strains can not be grown on above-mentioned M9 substratum, this 4 strain bacterium had both been expressed two valency LPS-O polysaccharide antigens, each group of stably express dysentery bacterium common Ipas proteantigen again, aroD genetically deficient, and have invasive ability.This 4 strain bacterium is dysentery multivalent genetic engineering vaccine strain (inv +Ipas +Δ aroD) FS.
(2) screening of dysentery multivalent genetic engineering vaccine strain
According to the IpaA that GeneBank has announced, IpaB, IpaC, IpaD gene order design PCR primer is a template with Salmonellas or intestinal bacteria, obtains IpaA, IpaB, IpaC, IpaD gene respectively by gene amplification, is implemented in pQE 30On (purchasing invitrogen company) prokaryotic expression carrier, import DH5 α recipient bacterium and obtain IpaA, IpaB, IpaC, IpaD Recombinant Protein Expression, prepared IpaA, IpaB, IpaC, the IpaD recombinant protein antigen of purifying through ni-sepharose purification in the U.S..Add subcutaneous multiple spot immunity BALB/c mouse behind the incomplete Fu Shi adjuvant emulsion of equivalent respectively with IpaA, IpaB, IpaC, the IpaD recombinant protein antigen of purifying, three times antibody titer is surveyed in the immunity back, get its immune BALB/c mouse spleen, preparation splenocyte and myeloma cell (SP2/0) are merged, the hybridoma cell strain of screening IpaA, IpaB, IpaC, IpaD antibody positive.Adopt limiting dilution to obtain to produce the hybridoma cell strain of antibody; and further identify that with ELISA IpaA, IpaB, IpaC, IpaD hybridoma cell strain secretory antibody are at IpaA; IpaB; IpaC; IpaD protective epitope's monoclonal cell strain (being respectively: 3G11,2E8,5F2,5D3) is respectively IgG2a, IgG1b, IgG1a, IgG2b through the antibody subtype Analysis and Identification.
Adopt Western blotting hybridization to detect the dysentery multivalent genetic engineering vaccine strain and express IpaA, IpaB, IpaC, the antigenic situation of IpaD invasin protein, concrete grammar is: sample on dysentery multivalent genetic engineering vaccine strain and the SDS-PAGE sample-loading buffer heated and boiled, carry out 10%SDS-PAGE, respectively with above-mentioned at IpaA, IpaB, IpaC, IpaD protective epitope's antibody is one anti-, sheep anti-mouse igg (available from Britain Amersham company) with the HRP mark is the two anti-Western blotting that carry out, and results of hybridization shows the IpaA hybridization band that has obtained 70kDa in the dysentery multivalent genetic engineering vaccine strain sample, the IpaB hybridization band of 62kDa, the IpaC hybridization band of 42kDa, the IpaD of 36kDa; Illustrate that 4 strain dysentery multivalent genetic engineering vaccine strains of the present invention can express IpaA, IpaB, IpaC, IpaD.
2, the evaluation of 4 strain dysentery multivalent genetic engineering vaccine strains
1. invade phenotypic evaluation
Song Nei Shi, Fu Shi 2a type II, group's 3,4 reference cultures (purchasing) in the national drug biological products assay institute.
The ordinary flat line is carried out in dilution after the dysentery multivalent genetic engineering vaccine strain activation culture, cultivate 20-22h for 37 ℃, choose single bacterium colony and Fu Shi type II, group 3,4 and Song Nei Shi I phase factor and invasin protein IpaA, IpaB, IpaC, IpaD antibody do slide agglutination test, observe the invasion phenotype.Concrete grammar is: respectively Song Nei Shi, Fu Shi 2a type II, group's 3,4 reference cultures (purchasing in Nat'l Pharmaceutical ﹠ Biological Products Control Institute) are dripped in slide, scrape and get an amount of lawn, add corresponding invasin protein IpaA, IpaB, IpaC, the agglutination reaction of IpaD antibody respectively, the result shows, strong agglutination reaction all takes place with IpaA, IpaB, IpaC, IpaD antibody in multivalence Song Shi, Fu Shi and invasin protein antigen, performance Song Nei Shi +++, Fu Shi 2a type II +++, group 3,4 +++And IpaA +++, IpaB +++, IpaC +++, IpaD +++Be the strong agglutination reaction of multivalence (" +++" represent strong agglutination reaction).
The evaluation that A, invasin protein are expressed:
Select for use the Hayes broth culture to cultivate strain of 18h dysentery multivalent genetic engineering vaccine and dysentery bivalent gene engineering vaccine FSM2117 (doing contrast) respectively, abandoning supernatant after centrifugal washes once with physiological saline, the recovery original volume adds equivalent sample preparation liquid (1% tetrabromophenol sulfonphthalein) and boils, application of sample carries out the 10%SDS-PAGE electrophoresis, seal with bovine serum albumin-PBS on the transfer film, add corresponding mouse-anti IpaA then, IpaB, IpaC, the IpaD monoclonal antibody is one anti-, ambient temperature overnight PBS washes several times, and the 37 ℃ of temperature of sheep anti-mouse igg (available from Britain Amersham company) that add again with the HRP mark are bathed, and PBS washes back DAB colour developing several times.WB (western blot test), ELISA, Immunoblot result show, the antibody of dysentery multivalent genetic engineering vaccine strain and Song Nei Shi, Fu Shi 2a type II, group 3,4 and invasin protein IpaA, IpaB, IpaC, IpaD is the polyvalent antigen positive reaction, and dysentery bivalent gene engineering vaccine FSM2117 and Song Nei Shi, Fu Shi 2a type II, group's 3,4 LPS-O is positive, but with the reaction that is negative of the monoclonal antibody of invasin protein IpaA, IpaB, IpaC, IpaD.
The evaluation of B, Congo red adsorption experiment:
Dysentery multivalent genetic engineering vaccine strain, dysentery bivalent gene engineering vaccine FSM2117, T32 attenuated strain (negative control), F2a-12 virulent strain (positive control) are inoculated in the LB broth culture respectively, 37 ℃ of joltings are spent the night, be seeded in respectively to contain on the 0.01% Congo red LB plate and rule, again 37 ℃ of overnight incubation.The result shows, it is translucent being creamy white that dysentery bivalent gene engineering vaccine FSM2117, T32 attenuated strain do not absorb Congo red lawn, the F2a-12 virulent strain absorbs Congo red lawn and is strong redness, and the dysentery multivalent genetic engineering vaccine strain absorbs Congo red lawn for red, but degree is lower than the F2a-12 virulent strain, its degree and between the feminine gender and the positive.
The evaluation of C, contact hemolysis experiment:
Dysentery multivalent genetic engineering vaccine strain, dysentery bivalent gene engineering vaccine FSM2117, T32 attenuated strain (negative control), F2a-12 virulent strain (positive control) are inoculated in the Hayes broth culture respectively, 37 ℃ of joltings are spent the night, centrifugal washing twice, to preserve in the liquid guinea pig blood cell centrifugation simultaneously washes 4 times, and with guinea pig blood cell and 37 ℃ of 2h of testing sample mixing, centrifuging and taking supernatant then, ultraviolet detection 570nm OD value.The result shows that dysentery multivalent genetic engineering vaccine strain OD value is significantly less than the F2a-12 virulent strain, and apparently higher than Non-Invasive dysentery bivalent gene engineering vaccine FSM2117.
The evaluation of D, Hela cell invasion experiment:
With 4 * 10 of cultivation 4The Hela cell of individual cell/ml is put into the bottle that little cover glass is housed and is cultivated 24h, is 5 * 10 with the bacterial strain dilution to be checked of newly cultivating 8CFU/ml, equivalent adds Hela cell bottle and infects 2h, takes out this slide PBS and washes 4 times, fix with methyl alcohol, Giemsa dyeing, mirror is 1000 Hela cells of meter down, calculate the invasion number of bacterial strain to the Hela cell.The result shows that it is 80% that the F2a-12 virulent strain is invaded the Hela cell count, and it is 36% that the dysentery multivalent genetic engineering vaccine bacterial strain is invaded the Hela cell count, and dysentery bivalent gene engineering vaccine FSM2117 intrusion Hela cell count is 2%.
2. security is identified
5,000,000,000 CFU dysentery multivalent genetic engineering vaccine strains are put into the conjunctival sac of the eyes of cavy, and the another eyes are not done any processing as blank, carry out dysentery multivalent genetic engineering vaccine cavy angle conjunctival butter according to a conventional method, the result shows that the dysentery multivalent genetic engineering vaccine strain is to the cavy no pathogenicity; The mouse virulence experiment reaches the vaccine safety requirements, and (mouse peritoneal injects 5 * 10 9Cfu does not have dead).The oral 20,000,000,000 CFU dysentery multivalent genetic engineering vaccine strains of monkey body, mouse peritoneal inject 1,000,000,000 CFU dysentery multivalent genetic engineering vaccine strains and all have no adverse reaction.Dysentery multivalent genetic engineering vaccine strain mouse LD 50Detect, the result proves the mouse LD of dysentery multivalent genetic engineering vaccine strain 50Be worth suitable with dysentery bivalent gene engineering vaccine FSM2117.So far finish toxicity and the virulence experiment of dysentery polyvalent vaccine and all identify, prove that this dysentery multivalent genetic engineering vaccine strain is safe in utilization.
3. stability is identified
Divide supplementary biography 60 generations the seed bank and the work storehouse bacterial strain of dysentery multivalent genetic engineering vaccine strain; by the Congo red absorption of the biological phenotype of difference; contact hemolysis; Hela cell invasion identification invasin protein antigen monoclonal antibody (3G11; 2E8; 5F2; 5D3); with full bacterium WB (western blot test); ELISA; methods such as Immunoblot are carried out two valency LPS-O protective antigens; the observation of Ipas invasin protein antigen and biological phenotypic stability; experimental result shows; the dysentery multivalent genetic engineering vaccine strain passed for 60 generations and preserves 5 years energy stably express protectiveness LPS-O antigen and invasin protein IpaA; IpaB; IpaC; IpaD, and biological phenotype such as invasion is stable.
To the oral capsule or the collunarium freeze-dried preparation of the different batches that lasts 5 years and nearly 200 routine volunteers are got rid of vaccine, the system that carries out biochemistry, genetics and antigen presentation one by one detects, proof is got rid of bacterium and oral capsule vaccine and collunarium vaccine at aspect indifferences such as plasmid size, biochemical characteristic, antigen presentation and cavy corneal tests, consistent with a large amount of animal test results in laboratory, prove that the dysentery multivalent genetic engineering vaccine strain has good stability.
Preserve the finished product preparation in 1 year,, all do not have change, prove that thus the dysentery multivalent genetic engineering vaccine strain has good stability at aspects such as genetics, biochemical, antigen presentations except that dysentery multivalent genetic engineering vaccine strain viable count has the decline of 5-8%.
4. immunogenicity is identified
A) with dysentery multivalent genetic engineering vaccine strain oral immunity mouse 3 times, each 0.1 hundred million CFU, use dysentery bivalent gene engineering vaccine FSM2117 oral immunity mouse 3 times simultaneously, each 1,000,000,000 CFU, each 14d at interval, 7d gathers the production of blood, lung-douching fluid and intestines, reproductive tract washing fluid detection IgA, IgG specific antibody after the last immunity.ELISA result shows, the anti-Fu Shi of dysentery multivalent genetic engineering vaccine strain, anti-Song Nei Shi and IpaA, IpaB, IpaC, it is respectively (1280,640 and 640,640,640,320) that IpaD serum IgA specific antibody is tired, and IgG is respectively (2560,1280 and 640,640,640,640); It is respectively (2560,2560 and 1280,1280,1280,12800) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (2560,1280 and 1280,1280,1280,1280); It is respectively (1280,1280 and 640,640,640,640) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (1280,640 and 320,640,320,640); It is respectively (1280,640 and 640,640,640,640) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (1280,640 and 320,320,320,320).Simultaneously ELISA result shows, the anti-Fu Shi of dysentery bivalent gene engineering vaccine strain FSM2117, anti-Song Nei Shi serum IgA specific antibody is tired is respectively (640,640), and IgG is respectively (1280,1280); It is respectively (1280,1280) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (1280,1280); It is respectively (1280,640) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (640,320); It is respectively (640,320) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (640,320).The result shows that special IgG of dysentery multivalent genetic engineering vaccine strain oral immunity mouse and IgA antibody are higher than the dysentery bivalent gene engineering vaccine.Especially more obvious with the multivalence specific antibody reaction of blood and lung-douching fluid, and can induce reproductive tract and the interior antibody response of intestines.
B) with dysentery multivalent genetic engineering vaccine strain collunarium immune mouse 3 times, each 0.001 hundred million CFU, use dysentery bivalent gene engineering vaccine FSM2117 collunarium immune mouse 3 times simultaneously, each 0.1 hundred million CFU, each 14d at interval, 7d gathers the reaction of blood, lung-douching fluid and intestines, reproductive tract washing fluid IgA, IgG specific antibody after the last immunity.ELISA result shows, the anti-Fu Shi of dysentery multivalent genetic engineering vaccine strain, anti-Song Nei Shi and IpaA, IpaB, IpaC, it is respectively (2560,1280 and 1280,640,640,640) that IpaD serum IgA specific antibody is tired, and IgG is respectively (5120,2560 and 1280,1280,1280,12800); It is respectively (2560,1280 and 1280,1280,1280,12800) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (5120,2560 and 1280,1280,640,1280); It is respectively (2560,1280 and 1280,640,640,640) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (1280,640 and 640,640,640,640); It is respectively (2560,1280 and 1280,6400,640,640) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (1280,640 and 640,640,320,320).Simultaneously ELISA result shows, the anti-Fu Shi of dysentery bivalent gene engineering vaccine FSM2117, anti-Song Nei Shi serum IgA specific antibody is tired is respectively (1280,640), and IgG is respectively (1280,1280); It is respectively (1280,1280) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (2560,1280); It is respectively (1280,640) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (640,640); It is respectively (640,320) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (640,320).The result shows that special IgG of dysentery multivalent genetic engineering vaccine strain collunarium immune mouse and IgA antibody are higher than dysentery bivalent gene engineering vaccine FSM2117.Especially more obvious with the multivalence specific antibody reaction of blood and lung-douching fluid, and can induce reproductive tract and the interior antibody response of intestines.
C) with dysentery multivalent genetic engineering vaccine strain oral immunity rhesus monkey 3 times, each 0.2 hundred million CFU, use dysentery bivalent gene engineering vaccine FSM2117 oral immunity rhesus monkey 3 times simultaneously, each 5.0 hundred million CFU, each 14d at interval, 7d gathers the reaction of blood, lung-douching fluid and intestines, reproductive tract washing fluid IgA, IgG specific antibody after the last immunity.ELISA result shows, the anti-Fu Shi of dysentery multivalent genetic engineering vaccine strain, anti-Song Nei Shi and IpaA, IpaB, IpaC, it is respectively (2560,640 and 640,640,640,640) that IpaD serum IgA specific antibody is tired, and IgG is respectively (2560,1280 and 1280,1280,640,640); It is respectively (6400,2560 and 2560,1280,2560,12800) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (5120,1280 and 1280,1280,2560,1280); It is respectively (2560,1280 and 1280,640,640,640) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (2560,1280 and 640,640,640,640); It is respectively (2560,1280 and 640,1280,640,640) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (1280,640 and 640,640,640,640).Simultaneously ELISA result shows, the anti-Fu Shi of dysentery bivalent gene engineering vaccine FSM2117, anti-Song Nei Shi serum IgA specific antibody is tired is respectively (1280,640), and IgG is respectively (1280,640); It is respectively (2560,1280) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (1280,1280); It is respectively (640,640) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (640,640); It is respectively (320,160) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (640,160).The result shows that special IgG of dysentery multivalent genetic engineering vaccine strain oral immunity rhesus monkey and IgA antibody are higher than dysentery bivalent gene engineering vaccine FSM2117.Especially more obvious with the multivalence specific antibody reaction of blood and lung-douching fluid, and can induce reproductive tract and the interior antibody response of intestines.
D) with dysentery multivalent genetic engineering vaccine strain collunarium immunity rhesus monkey 3 times, each 0.005 hundred million CFU, use dysentery bivalent gene engineering vaccine FSM2117 collunarium immunity rhesus monkey 3 times simultaneously, each 0.5 hundred million CFU, each 14d at interval, 7d gathers the reaction of blood, lung-douching fluid and intestines, reproductive tract washing fluid IgA, IgG specific antibody after the last immunity.ELISA result shows, the anti-Fu Shi of dysentery multivalent genetic engineering vaccine strain, anti-Song Nei Shi and IpaA, IpaB, IpaC, it is respectively (2560,1280 and 1280,1280,1280,640) that IpaD serum IgA specific antibody is tired, and IgG is respectively (6400,2560 and 1280,1280,640,1280); It is respectively (6400,5120 and 2560,2560,2560,25600) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (5120,5120 and 2560,2560,2560,1280); It is respectively (2560,1280 and 1280,1280,1280,1280) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (2560,1280 and 1280,1280,640,1280); It is respectively (2560,1280 and 1280,1280,1280,640) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (1280,1280 and 1280,640,12800,640).Simultaneously ELISA result shows, the anti-Fu Shi of dysentery bivalent gene engineering vaccine FSM2117, anti-Song Nei Shi serum IgA specific antibody is tired is respectively (1280,1280), and IgG is respectively (1280,1280); It is respectively (5120,2560) that lung-douching fluid sIgA specific antibody is tired, and IgG is respectively (1280,1280); It is respectively (640,320) that intestines washing lotion sIgA specific antibody is tired, and IgG is respectively (640,320); It is respectively (640,320) that reproductive tract washing fluid sIgA specific antibody is tired, and IgG is respectively (640,320).The result shows that dysentery multivalent genetic engineering vaccine strain collunarium immunity special IgG of rhesus monkey and IgA antibody are higher than dysentery bivalent gene engineering vaccine FSM2117.Especially more obvious with the multivalence specific antibody reaction of blood and lung-douching fluid, and can induce reproductive tract and the interior antibody response of intestines.
More than in the intravital result of mouse, rhesus monkey simultaneously as seen, collunarium is nearly 1% consumption of oral immunity dosage, all produced better immunogenicity mouse, rhesus monkey, and the collunarium immunity is better than the effect of oral immunity approach.
5. immune protective is identified
On, two approach immune mouses of collunarium oral, the rhesus monkey animal model, use 100LD respectively at existing dysentery multivalent genetic engineered vaccine, dysentery BIVALENT VACCINE FOR NEONTAL 50Fu Shi bacillus, Song Nei Shi virulent strain (purchasing in Nat'l Pharmaceutical ﹠ Biological Products Control Institute) collunarium, oral challenge are observed the immune protective effect of dysentery multivalent genetic engineered vaccine.The result shows, dysentery multivalent genetic engineered vaccine oral immunity mouse is 90%, is 84% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain, and the collunarium immune mouse is 95%, is 88% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain; Dysentery multivalent genetic engineered vaccine oral immunity rhesus monkey is 92%, is 88% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain, and the collunarium immune mouse is 98%, is 92% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain.And dysentery BIVALENT VACCINE FOR NEONTAL FSM2117 oral immunity mouse is 50%, is 41% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain, and the collunarium immune mouse is 56%, is 48% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain; Dysentery BIVALENT VACCINE FOR NEONTAL FSM2117 oral immunity rhesus monkey is 46%, is 40% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain, and the collunarium immune mouse is 55%, is 48% to the immune protective effect of Song Nei Shi strain the immunoprotection of Fu Shi strain.
More than in mouse, the intravital immune protective effect result of rhesus monkey as seen; the collunarium immunizing dose consumes more than 100 times than oral reduction, and the dysentery multivalent genetic engineering vaccine strain has improved nearly more than 30% than dysentery bivalent gene engineering vaccine FSM2117 immune protective effect.Illustrate that dysentery multivalent genetic engineering vaccine strain immunogenicity and immune protective are better than dysentery bivalent gene engineering vaccine FSM2117.
6. human safety, immunogenicity and protectiveness are identified
Finish dysentery multivalent genetic engineering vaccine strain laboratory study, on the safe and effective basis of proof dysentery multivalent genetic engineering vaccine strain laboratory animal, continuous 5 years in five different provinces, city, area, 5-59 year is amounted to 20,000 surplus the people carry out 3 oral dysentery multivalent genetic engineering vaccine strains of whole process.Security, immunogenicity and the protection effect of dysentery multivalent genetic engineering vaccine strain have been carried out strict examination and evaluation result shows:
A) dysentery multivalent genetic engineering vaccine strain people takes safety: the dysentery multivalent genetic engineering vaccine strain is to 10634 routine volunteer oral's immunizing dose 10,000,000,000 CFU, to 10000 routine volunteer's collunarium immunizing dose 5,000,000,000 CFU, and its side reaction rate is respectively 0.136%, 0.108%; Dysentery bivalent gene engineering vaccine FSM2117 is to 5000 routine volunteer oral's immunizing dose 10,000,000,000 CFU, to 3800 routine volunteer's collunarium immunizing dose 5,000,000,000 CFU, and its side reaction rate is respectively 0.114%, 0.110%; Use 0.5% gelatin, oral, the form of nose drops of 5% sucrose, 0.2% vitamins C, 0.1% thiaminogen, 0.1% skim-milk preparation dressing preparation is as placebo, to 5000 routine volunteer oral's immunity placebo 100g, to 5000 routine volunteer's collunarium immunity placebo 10g, placebo side reaction rate is respectively 0.086%, 0.119%.There is not difference from side reaction between above dysentery multivalent genetic engineering vaccine strain, dysentery bivalent gene engineering vaccine FSM2117 and placebo.Oral, collunarium dysentery multivalent genetic engineering vaccine strain safety that the reference uses.
B) dysentery multivalent genetic engineering vaccine strain oral immunity has good immunogenicity and immune protective: by at random, balanced, double blinding principle; successively 5353 routine volunteers are carried out oral immunity 1.0 hundred million CFU; immunity three times; immunity was respectively for 0,2,4 weeks pitch time; and successively 1100 routine volunteers are carried out oral immunity 4,000,000,000 CFU with dysentery bivalent gene engineering vaccine FSM2117; immunity three times, immunity was respectively for 0,2,4 weeks pitch time.180d after both immunity are finished gathers serum, ight soil and saliva, and the ELISA that carries out anti-Fu Shi, anti-Song Nei Shi and Ipas specific IgA, IgG detects.ELISA result shows, the anti-Fu Shi of dysentery multivalent genetic engineering vaccine strain, anti-Song Nei Shi and IpaA, IpaB, IpaC, it is respectively 1280,1280 and 640,640,640,640 that IpaD serum IgA specific antibody is tired, and IgG is respectively 1280,1280 and 640,640,640,320; It is respectively 1280,1280 and 640,640,320,320 that ight soil sIgA specific antibody is tired, and IgG is respectively 1280,640 and 640,320,320,160; It is respectively 640,320 and 160,160,160,160 that saliva sIgA specific antibody is tired, and IgG is respectively 640,640 and 320,320,160,320.Simultaneously ELISA result shows, the anti-Fu Shi of dysentery bivalent gene engineering vaccine FSM2117, anti-Song Nei Shi serum IgA specific antibody is tired is respectively 640,320, and IgG is respectively 640,640; It is respectively 320,160 that ight soil sIgA specific antibody is tired, and IgG is respectively 640,320; It is respectively 320,160 that saliva sIgA specific antibody is tired, and IgG is respectively 160,80.The result shows that dysentery multivalent genetic engineering vaccine strain human oral special IgG of immunity and IgA antibody are higher than dysentery bivalent gene engineering vaccine FSM2117.The two valency specific IgA of the ight soil 4 multiplication high rates of tiring before than the clothes seedling are 68%-81%, and the saliva bivalent antibody 4 multiplication high rates of tiring are 75-91%, and invasin protein antibody is arranged.Prove that fully the dysentery multivalent genetic engineering vaccine strain has good multivalent immunogenic.Can effectively induce and produce special multivalence mucoantibody reaction.Further collect the case of suffering from diarrhoea half a year, by the laboratory bacteriological detection, make a definite diagnosis, add up, the result shows that dysentery multivalent genetic engineering vaccine strain oral immunity provides 91.8% to children, adult 86.5% protection ratio.Being 89.8% to Fu Shi 2a protection ratio wherein, to Song Nei Shi 84.6%, is 76.8% to the protection ratio of special-shaped dysentery.
C) immunity of dysentery multivalent genetic engineering vaccine strain collunarium has good immunogenicity and protectiveness: by at random, balanced, double blinding principle; successively 3000 routine volunteers are carried out collunarium immunity 0.01 hundred million CFU; immunity three times; immunity was respectively for 0,2,4 weeks pitch time; and successively 1400 routine volunteers are carried out collunarium immunity 1.0 hundred million CFU with dysentery bivalent gene engineering vaccine FSM2117; immunity three times, immunity was respectively for 0,2,4 weeks pitch time.The detection of 180d collection serum, ight soil and the anti-Fu Shi of saliva, anti-Song Nei Shi and Ipas specific IgA, IgG after both immunity are finished.ELISA result shows, the anti-Fu Shi of dysentery multivalent genetic engineering vaccine strain, anti-Song Nei Shi and IpaA, IpaB, IpaC, it is respectively (2560,1280 and 1280,1280,640,640) that IpaD serum IgA specific antibody is tired, and IgG is respectively (2560,2560 and 640,640,640,320); It is respectively (1280,1280 and 640,1280,640,640) that ight soil sIgA specific antibody is tired, and IgG is respectively (1280,1280 and 640,640,640,640); It is respectively (640,640 and 320,320,320,160) that saliva sIgA specific antibody is tired, and IgG is respectively (640,320 and 320,320,640,640).Simultaneously ELISA result shows, the anti-Fu Shi of dysentery bivalent gene engineering vaccine FSM2117, anti-Song Nei Shi serum IgA specific antibody is tired is respectively (640,320), and IgG is respectively (1280,640); It is respectively (640,320) that ight soil sIgA specific antibody is tired, and IgG is respectively (640,320); It is respectively (640,640) that saliva sIgA specific antibody is tired, and IgG is respectively (320,320).The result shows that dysentery multivalent genetic engineering vaccine strain people collunarium special IgG of immunity and IgA antibody are higher than dysentery bivalent gene engineering vaccine FSM2117.The two valency specific IgA of the ight soil 4 multiplication high rates of tiring before than collunarium seedling are 78%-88%, and the saliva bivalent antibody 4 multiplication high rates of tiring are 70-92%, and invasin protein antibody is arranged.Prove that fully the dysentery multivalent genetic engineering vaccine strain has good multivalent immunogenic.Can effectively induce and produce special multivalence mucoantibody reaction.Further collect the case of suffering from diarrhoea half a year, by the laboratory bacteriological detection, make a definite diagnosis, add up, the result shows that the immunity of dysentery multivalent genetic engineering vaccine strain collunarium provides 98.0% to children, adult 89.6% protection ratio.Being 93.4% to Fu Shi 2a protection ratio wherein, to Song Nei Shi 88.9%, is 89.1% to the protection ratio of special-shaped dysentery.
The production of embodiment 2, dysentery multivalent genetic engineering vaccine preparation
The production technique of dysentery multivalent genetic engineering vaccine oral capsule preparation is as follows: with the dysentery multivalent genetic engineering freeze-dried vaccine young plant (4,000,000,000 CFU/ prop up) in the seed pipe, (fresh beef 7500g adds 11250ml distilled water and boils 40min to insert the Hou Shi liquid medium, be cooled to 45 ℃ of fresh pig pancreas 1500mg that add homogenate, transfer pH8.0, add trichloromethane 200ml, digestion 7d with preceding 4 times of dilutions, and adds sodium-chlor 0.5%, pH7.2-7.4 is standby for accent) or LB substratum (peptone 10g, yeast leach liquor 5g, sodium-chlor 10g adds water to 1000ml, pH is 7.2-7.5) the 3.0L culturing bottle in, 37 ℃, 150-200rpm shaking culture 13-15h directly injects the 10L culturing bottle that 8500ml Hou Shi liquid medium or LB substratum are housed, 37 ℃, static cultivation 6-8h injects the 180L culture tank that 180 liters of Hou Shi liquid mediums or LB substratum are housed, 37 ℃, static cultivation 6-8h, regulate pH7.2, centrifugal, collect thalline.Vaccine and medical dressing composition mixture are made in single agent packaging container, are used to produce dysentery multivalent genetic engineering freeze-drying vaccine oral capsule, form of nose drops.
1; the production of dysentery multivalent genetic engineering vaccine lyophilized oral capsule formulation: the above-mentioned wet thallus of collecting is suspended from contains 0.5% gelatin; 5% sucrose; 0.2% vitamins C; 0.1% thiaminogen; 0.1% skim-milk; in the phosphate buffered saline buffer of pH7.2; the concentration that makes bacterium liquid is 10,000,000,000 CFU/ml; be put in the freeze-drying dish;-30 ℃; 2-4h; vacuum reaches 85uHg, is warmed up to 30 ℃, constant temperature; dry 20h; obtain dysentery multivalent genetic engineering freeze-drying vaccine lyophilized powder, put 6-8 ℃, carry out pure bacterium test; the result shows survival rate>40%; moisture<3% is by the Congo red absorption of the biological phenotype of difference; contact hemolysis; Hela cell invasion identification protecting antigen monoclonal antibody (3G11; 2E8; 5F2; 5D3), with full bacterium WB; ELISA; screening of methods such as Immunoblot and evaluation invasion phenotype (inv +) ability.Experimental result shows that the dysentery multivalent genetic engineering vaccine lyophilized powder can be expressed two valency LPS-O protective antigens and Ipas antigen.With dysentery multivalent genetic engineering vaccine lyophilized powder and sucrose, sodium starch glycolate, lactose, amylum pregelatinisatum, Magnesium Stearate mixing by a certain percentage, under oral capsule GMP condition, prepare capsule formulation.Make consisting of of every oral capsule: dysentery multivalent genetic engineering vaccine strain 1.0 hundred million CFU viable bacterias, sucrose 15mg, sodium starch glycolate 15mg, lactose 20mg, amylum pregelatinisatum 20mg, Magnesium Stearate 0.4mg.
2, the production of dysentery multivalent genetic engineering freeze-drying vaccine form of nose drops
The above-mentioned multivalent genetic engineering vaccine of collecting is suspended from contains 0.5% gelatin, 5% sucrose, 0.2% vitamins C, 0.1% thiaminogen, 0.1% skim-milk, in the phosphate buffered saline buffer of pH7.2, the viable count that makes bacterium liquid is 1,000,000,000 CFU/ml, in the packing freeze-drying dish,-30 ℃, 2-4h, vacuum reaches 85uHg, be warmed up to 30 ℃, constant temperature, dry 20h obtains dysentery multivalent genetic engineering freeze-drying vaccine pulvis.Put 6-8 ℃; carry out pure bacterium test; the result shows survival rate>40%; moisture<3%; by the Congo red absorption of the biological phenotype of difference, contact hemolysis, Hela cell invasion identification protecting antigen monoclonal antibody (3G11,2E8,5F2,5D3), with screening of methods such as full bacterium WB, ELISA, Immunoblot and evaluation invasion phenotype (inv +) ability.Experimental result shows that dysentery multivalent genetic engineering vaccine bacterium lyophilized powder can be expressed two valency LPS-O protective antigens and Ipas antigen.Make consisting of of every bottle of form of nose drops: dysentery multivalent genetic engineering vaccine 0.1 hundred million/bottle CFU freeze-drying viable bacteria, it is standby to be uniform suspension with preceding and 0.2ml/ bottle physiological saline (including 1%BL-9 (9-lauryl ether), 2% whiteruss) dissolving.
3, two kinds of dysentery multivalent genetic engineering vaccine preparations that step 1 and step 2 are obtained carry out following evaluation:
1) purity test: after the goods dilution, (fresh beef 750g adds 1125ml distilled water and boils 40min to be inoculated in the big agar slant of Hou Shi, be cooled to 45 ℃ of fresh pig pancreas 150mg that add homogenate, transfer pH8.0, and adding trichloromethane 20ml, digestion 7d, with preceding 4 times of distilled water dilutings, and adding sodium-chlor 0.5%, transfer pH7.2-7.4, agar powder 1.5g) or LB agar slant (peptone 1.0g, yeast leach liquor 0.5g, sodium-chlor 1.0g, agar powder 1.5g adds water to 100ml), cultivate 48h for 37 ℃, two kinds of dysentery multivalent genetic engineering vaccine preparations all do not have varied bacteria growing.
2) antigen presentation: (fresh beef 7500g adds 11250ml distilled water and boils 40min the goods vaccine after will diluting in the big agar slant of Hou Shi, be cooled to 45 ℃ of fresh pig pancreas 1500mg that add homogenate, transfer pH8.0, and adding trichloromethane 200ml, digestion 7d, with preceding 4 times of distilled water dilutings, and adding sodium-chlor 0.5%, transfer pH7.2-7.4 standby,) or LB agar slant (peptone 1.0g, yeast is invaded fluid 0.5g, sodium-chlor 1.0g, agar powder 1.5g, add water to 100ml) line, cultivate 20-22h for 37 ℃, choose single bacterium colony and Fu Shi type II, group 3,4 and Song Nei Shi I phase factor, with invasin protein IpaA, IpaB, IpaC, IpaD serum is done slide agglutination test, and the above-mentioned two kinds of dysentery multivalent genetic engineering vaccine preparations of result all are the strong agglutination reaction of 4+ multivalence.
3) viable bacteria rate and water content detection: carry out live bacterial count with turbidimetry, survey moisture content with the Kai Shi method, three pull on state two kinds of dysentery multivalent genetic engineering vaccine preparation viable bacteria rates and the water content detection result as shown in table 1, three to pull on the biochemical reaction of stating two kinds of dysentery multivalent genetic engineering vaccine freeze-dried preparation as shown in table 2.
Two kinds of dysentery multivalent genetic engineering vaccine freeze-dried preparation of table 1. viable bacteria rate and water content detection result
Lot number Water content % Viable bacteria rate (%)
Before doing After doing After doing/before doing
6010 6011 6012 1.81 2.54 2.13 53 38 32.6 28 21 23.6 53 55 72
Annotate: 6010 and 6011 is capsule, and 6012 is nasal drop
With the dysentery multivalent genetic engineering vaccine strain of incubated overnight, be inoculated in the biochemical reaction pipe (purchasing) of glucose, lactose, maltose, seminose and sucrose respectively in Nat'l Pharmaceutical ﹠ Biological Products Control Institute, cultivate 24h for 37 ℃, observe its reaction, reaction tubes becomes blue look positive (+) by green, and two kinds of dysentery multivalent genetic engineering vaccine preparation biochemical reactions the results are shown in Table 2
Two kinds of dysentery multivalent genetic engineering vaccine preparations of table 2. biochemical reaction result
Batch sugar Glucose Lactose Maltose Seminose Sugarcane
6010 6011 6012 FSM2117 + + + + - - - - + + + + + + + + - - - -
Annotate: 6010 and 6011 is the dysentery multivalent genetic engineering vaccine oral capsule, and 6012 is the dysentery multivalent genetic engineering vaccine nasal drop; FSM2117 is a dysentery bivalent gene engineering vaccine oral preparations, "+" positive reaction, "-" negative reaction.
4) rabbit antibody produces test: get respectively to pull at every turn and state 1 in two kinds of preparations, be diluted to 6-20 hundred million/ml with sterile saline, ear vein approach immune health New Zealand white big ear rabbit, totally three times (0.25ml, 0.5ml, 0.5ml), each 7 days at interval, 3 rabbit of every batch of goods immunity, serum antibody titer is surveyed in blood sampling in 3-10 days after the last immunity.The main points that ELISA measures are, wrap respectively by elisa plate with Sh.Sonnei, Sh.flexneri, Ipas respectively, put 4 ℃ of refrigerator overnight, wash plate with PBS, the immunize rabbit serum that adds doubling dilution is put 37 ℃ of incubator 2.0h, washes plate with carbonic acid buffer, the enzyme mark goat anti-rabbit antibody that adds dilution is put 37 ℃ of incubator 1.0h, use 2N sulfuric acid stopped reaction subsequently, on the uv-spectrophotometric instrument, measure, and the conversion antibody titer.The result is as shown in table 3, shows that above-mentioned two kinds of dysentery multivalent genetic engineering vaccine freeze-dried preparation all have good immunogenicity.
The serum agglutinating antibody of two kinds of dysentery multivalent genetic engineering vaccine freeze-dried preparation of table 3. is tired
Batch Lot number Antibody titer
Sh.Sonnei. Sh.flexneri Ipas
6010 1 2 3 1280 1280 2560 5120 5120 10240 640 1280 1280
6011 1 2 3 1280 320 1280 10240 10240 10240 640 1280 2560
6012 1 2 3 1280 1280 5120 5120 5120 5120 1280 1280 2560
Annotate: 6010 and 6011 is capsule, and 6012 is nasal drop.
5) virulence test: adopt the cavy corneal test, get lawn (the diameter 3mm after above-mentioned two kinds of dysentery multivalent genetic engineering vaccine preparations activate, about 5,000,000,000 viable bacterias), be coated with in the conjunctival sac of cavy angle, observed 7 days, three pull on and state two kinds of dysentery multivalent genetic engineering vaccine freeze-dried preparation and all do not cause any inflammatory reaction.
6) Ipas detects: (fresh beef 750g adds 1125ml distilled water and boils 40min with above-mentioned two kinds of dysentery multivalent genetic engineering vaccine freeze-dried preparation inoculation Hou Shi liquid medium, be cooled to 45 ℃ of fresh pig pancreas 150mg that add homogenate, transfer pH8.0, and adding trichloromethane 20ml, digestion 7d, with preceding 4 times of distilled water dilutings, and adding sodium-chlor 0.5%, pH7.2-7.4 is standby for accent) or LB substratum (peptone 10g, yeast leach liquor 5g, sodium-chlor 10g, add water to 1000ml, pH7.2-7.5), treat that bacteria concentration reaches 10 10Cfu/ml (cultivating 20 hours for 37 ℃) uses the 10%SDS-PAGE electrophoresis detection, and the result shows that dysentery multivalent genetic engineering vaccine has all increased the antigen protein of invasin protein than the strain of dysentery bivalent gene engineering vaccine.
7) the invasion phenotypic evaluation of system: the oral capsule of the different batches that lasts 2 years or intranasal formulation are gathered ight soil to nearly 200 routine volunteers carry out biochemistry one by one, the system of genetics and antigen presentation detects, dysentery multivalent genetic engineering vaccine that proof ight soil is discharged and oral and collunarium dysentery multivalent genetic engineering vaccine are in the plasmid size, biochemical characteristic, aspect indifferences such as antigen presentation and cavy corneal test, with the Congo red absorption of a large amount of animals in laboratory, contact hemolysis, Hela cell invasion test-results unanimity proves that dysentery multivalent genetic engineering vaccine has good invasion phenotype.
Sequence table
<160>8
<210>1
<211>633
<212>PRT
<213〉Shigella (Shigella)
<400>1
Met His Asn Val Asn Asn Thr Gln Ala Pro Thr Phe Leu Tyr Lys Ala
1 5 10 15
Thr Ser Pro Ser Ser Thr Glu Tyr Ser Glu Leu Lys Ser Lys Ile Ser
20 25 30
Asp Ile His Ser Ser Gln Thr Ser Leu Lys Thr Pro Ala Ser Val Ser
35 40 45
Glu Lys Glu Asn Phe Ala Thr Ser Phe Asn Gln Lys Cys Leu Asp Phe
50 55 60
Leu Phe Ser Ser Ser Gly Lys Glu Asp Val Leu Arg Ser Ile Tyr Ser
65 70 75 80
Asn Ser Met Asn Ala Tyr Ala Lys Ser Glu Ile Leu Glu Phe Ser Asn
85 90 95
Val Leu Tyr Ser Leu Val His Gln Asn Asp Leu Asn Phe Glu Asn Glu
100 105 110
Lys Gly Leu Gln Lys Ile Val Ala Gln Tyr Ser Glu Leu Ile Ile Lys
115 120 125
Asp Lys Leu Ser Gln Asp Ser Ala Phe Gly Pro Trp Ser Ala Lys Asn
130 135 140
Lys Lys Leu His Gln Leu Arg Gln Asn Ile Glu His Arg Leu Ala Leu
145 150 155 160
Leu Ala Gln Gln His Thr Ser Gly Glu Ala Leu Ser Leu Gly Gln Lys
165 170 175
Leu Leu Asn Thr Glu Val Ser Ser Phe Ile Lys Asn Asn Ile Leu Ala
180 185 190
Glu Leu Lys Leu Ser Asn Glu Thr Val Ser Ser Leu Lys Leu Asp Asp
195 200 205
Leu Val Asp Ala Gln Ala Lys Leu Ala Phe Asp Ser Leu Arg Asn Gln
210 215 220
Arg Lys Asn Thr Ile Asp Ser Lys Gly Phe Gly Ile Gly Lys Leu Ser
225 230 235 240
Arg Asp Leu Asn Thr Val Ala Val Phe Pro Glu Leu Leu Arg Lys Val
245 250 255
Leu Asn Asp Ile Leu Glu Asp Ile Lys Asp Ser His Pro Ile Gln Asp
260 265 270
Gly Leu Pro Thr Pro Pro Glu Asp Met Pro Asp Gly Gly Pro Thr Pro
275 280 285
Gly Ala Asn Glu Lys Thr Ser Gln Pro Val Ile His Tyr His Ile Asn
290 295 300
Asn Asp Asn Arg Thr Tyr Asp Asn Arg Val Phe Asp Asn Arg Val Tyr
305 310 315 320
Asp Asn Ser Tyr His Glu Asn Pro Glu Asn Asp Ala Gln Ser Pro Thr
325 330 335
Ser Gln Thr Asn Asp Leu Leu Ser Arg Asn Gly Asn Ser Leu Leu Asn
340 345 350
Pro Gln Arg Ala Leu Val Gln Lys Val Thr Ser Val Leu Pro His Ser
355 360 365
Ile Ser Asp Ala Val Gln Thr Phe Ala Asn Asn Ser Ala Leu Glu Lys
370 375 380
Val Phe Asn His Thr Pro Asp Asn Ser Asp Gly Ile Gly Ser Asp Leu
385 390 395 400
Leu Thr Thr Ser Ser Gln Glu Arg Ser Thr Asn Asn Ser Leu Ser Arg
405 410 415
Gly His Arg Pro Leu Asn Ile Gln Asn Ser Ser Thr Thr Pro Pro Leu
420 425 430
His Pro Glu Gly Val Thr Ser Ser Asn Asp Asn Ser Ser Asp Thr Thr
435 440 445
Lys Ser Ser Ala Ser Leu Ser His Arg Val Ala Ser Gln Ile Asn Lys
450 455 460
Phe Asn Ser Asn Thr Asp Ser Lys Val Leu Gln Thr Asp Phe Leu Ser
465 470 475 480
Arg Asn Gly Asp Thr Tyr Leu Thr Arg Glu Thr Ile Phe Glu Ala Ser
485 490 495
Lys Lys Val Thr Asn Ser Leu Ser Asn Leu Ile Ser Leu Ile Gly Thr
500 505 510
Lys Ser Gly Thr Gln Glu Arg Glu Leu Gln Glu Lys Ser Lys Asp Ile
515 520 525
Thr Lys Ser Thr Thr Glu His Arg Ile Asn Asn Lys Leu Lys Val Thr
530 535 540
Asp Ala Asn Thr Ile Asn Tyr Val Thr Glu Thr Asn Ala Asp Thr Ile
545 550 555 560
Asp Lys Asn His Ala Ile Tyr Glu Lys Ala Lys Glu Val Ser Ser Ala
565 570 575
Leu Ser Lys Val Leu Ser Lys Ile Asp Asp Thr Ser Ala Glu Leu Leu
580 585 590
Thr Asp Asp Ile Ser Asp Leu Lys Asn Asn Asn Asp Ile Thr Ala Glu
595 600 605
Asn Asn Asn Ile Tyr Lys Ala Ala Lys Asp Val Thr Thr Ser Leu Ser
610 615 620
Lys Val Leu Lys Asn Ile Asn Lys Asp
625 630
<210>2
<211>580
<212>PRT
<213〉Shigella (Shigella)
<400>2
Met His Asn Val Ser Thr Thr Thr Thr Gly Leu Pro Leu Ala Lys Ile
1 5 10 15
Leu Ala Ser Thr Glu Leu Gly Asp Asn Thr Ile Gln Ala Ala Asn Asp
20 25 30
Ala Ala Asn Lys Leu Phe Ser Leu Thr Ile Ala Asp Leu Ala Ala Asn
35 40 45
Lys Asn Ile Asn Thr Thr Asn Ala His Ser Thr Ser Asn Ile Leu Ile
50 55 60
Pro Glu Leu Lys Ala Pro Lys Ser Leu Asn Ala Ser Ser Gln Leu Thr
65 70 75 80
Leu Leu Ile Gly Asn Leu Ile Gln Ile Leu Gly Glu Lys Ser Leu Thr
85 90 95
Ala Leu Thr Asn Lys Ile Thr Ala Trp Lys Ser Gln Gln Gln Ala Arg
100 105 110
Gln Gln Lys Asn Leu Glu Phe Ser Asp Lys Ile Asn Thr Leu Leu Ser
115 120 125
Glu Thr Glu Gly Leu Thr Arg Asp Tyr Glu Lys Gln Ile Asn Lys Leu
130 135 140
Lys Asn Ala Asp Ser Lys Ile Lys Asp Leu Glu Asn Lys Ile Asn Gln
145 150 155 160
Ile Gln Thr Arg Leu Ser Glu Leu Ala Pro Asp Ser Pro Glu Asn Lys
165 170 175
Lys Leu Arg Arg Glu Glu Ile Gln Leu Thr Ile Lys Lys Asp Ala Ala
180 185 190
Val Lys Asp Arg Thr Leu Ile Glu Gln Lys Thr Leu Ser Ile His Ser
195 200 205
Lys Leu Thr Asp Lys Ser Met Gln Leu Glu Ser Leu Gln Glu Ser Arg
210 215 220
Lys Thr Glu Met Glu Arg Lys Ser Asp Glu Tyr Lys Glu Ile Asp Ser
225 230 235 240
Phe Ser Ala Phe Ser Asn Thr Ala Ser Ala Glu Gln Leu Ser Thr Gln
245 250 255
Gln Lys Ser Leu Thr Gly Leu Ala Ser Val Thr Gln Leu Met Ala Thr
260 265 270
Phe Ile Gln Leu Val Gly Lys Asn Asn Glu Glu Ser Leu Lys Asn Asp
275 280 285
Leu Ala Leu Phe Gln Ala Ala Glu Val Arg Lys Ala Glu Glu Leu Asn
290 295 300
Arg Val Met Gly Cys Val Gly Lys Ile Leu Gly Ala Leu Leu Thr Ile
305 310 315 320
Val Ser Val Val Ala Ala Ala Phe Ser Gly Gly Ala Ser Leu Ala Leu
325 330 335
Ala Ala Val Gly Leu Ala Leu Met Val Thr Asp Ala Ile Val Gln Ala
340 345 350
Ala Thr Gly Asn Ser Phe Met Glu Gln Ala Leu Asn Pro Ile Met Lys
355 360 365
Ala Val Ile Glu Pro Leu Ile Lys Leu Leu Ser Asp Ala Phe Thr Lys
370 375 380
Met Leu Glu Gly Leu Gly Val Asp Ser Lys Lys Ala Lys Met Ile Gly
385 390 395 400
Ser Ile Leu Gly Ala Ile Ala Gly Ala Leu Val Leu Val Ala Ala Val
405 410 415
Val Leu Val Ala Thr Val Gly Lys Gln Ala Ala Ala Lys Leu Ala Glu
420 425 430
Asn Ile Gly Lys Ile Ile Gly Lys Thr Leu Thr Asp Leu Ile Pro Lys
435 440 445
Phe Leu Lys Asn Phe Ser Ser Gln Leu Asp Asp Leu Ile Thr Asn Ala
450 455 460
Val Ala Arg Leu Asn Lys Phe Leu Gly Ala Ala Gly Asp Glu Val Ile
465 470 475 480
Ser Lys Gln Ile Ile Ser Thr His Leu Asn Gln Ala Val Leu Leu Gly
485 490 495
Glu Ser Val Asn Ser Ala Thr Gln Ala Gly Gly Asn Val Ala Ser Ala
500 505 510
Val Phe Gln Asn Asn Ala Ser Lys Asn Leu Ala Asp Leu Thr Leu Ser
515 520 525
Lys Tyr Gln Val Glu Gln Leu Ser Lys Tyr Ile Gly Asp Ala Ile Glu
530 535 540
Lys Phe Gly Gln Leu Gln Glu Val Ile Ala Glu Leu Leu Ala Ser Met
545 550 555 560
Ser Asn Ser Gln Ala Asn Arg Thr Asp Val Ala Lys Ala Ile Leu Gln
565 570 575
Gln Thr Thr Ala
580
<210>3
<211>363
<212>PRT
<213〉Shigella (Shigella)
<400>3
Met Glu Ile Gln Asn Thr Lys Ser Ala Pro Ile Leu Tyr Thr Asp Ile
1 5 10 15
Ser Thr Lys Gln Thr Gln Ser Ser Ser Glu Thr Gln Lys Ser Gln Asn
20 25 30
Tyr Gln Gln Leu Ala Ala His Ile Pro Leu Asn Val Gly Lys Asn Pro
35 40 45
Val Leu Thr Thr Thr Leu Asn Asp Asp Gln Leu Leu Lys Leu Ser Glu
50 55 60
Gln Val Gln His Asp Ser Glu Ile Ile Ala Arg Leu Thr Asp Lys Lys
65 70 75 80
Met Lys Asp Leu Ser Glu Met Ser His Thr Ile Thr Pro Glu Asn Thr
85 90 95
Leu Asp Ile Ser Ser Leu Ser Ser Asn Ala ValSer Leu Ile Ile Ser
100 105 110
Val Ala Val Leu Leu Ser Ala Leu Arg Thr Ala Glu Thr Arg Leu Gly
115 120 125
Ser Gln Leu Ser Leu Ile Ala Phe Asp Ala Thr Lys Ser Ala Ala Glu
130 135 140
Asn Ile Val Arg Gln Gly Leu Ala Ala Leu Ser Ser Ser Ile Thr Gly
145 150 155 160
Ala Val Thr Gln Val Gly Ile Thr Gly Ile Gly Ala Lys Lys Thr His
165 170 175
Ser Gly Ile Ser Glu Gln Lys Gly Ala Leu Arg Lys Asn Leu Ala Thr
180 185 190
Ala Gln Ser Leu Glu Lys Glu Leu Ala Gly Ser Lys Leu Gly Leu Asn
195 200 205
Lys Gln Ile Asp Thr Asn Ile Thr Ser Pro Gln Thr Asn Ser Ser Thr
210 215 220
Lys Ile Leu Gly Lys Asn Lys Leu Ala Pro Asp Asn Ile Ser Leu Ser
225 230 235 240
Thr Glu His Lys Thr Ser Leu Ser Ser Pro Asp Ile Ser Leu Gln Asp
245 250 255
Lys Ile Asp Thr Gln Arg Arg Ala Tyr Glu Leu Asn Thr Leu Ser Ala
260 265 270
Gln Gln Lys Gln Asn Ile Gly Arg Ala Thr Met Glu Thr Ser Ala Val
275 280 285
Ala Gly Asn Ile Ser Thr Ser Gly Gly Arg Tyr Thr Ser Ala Leu Glu
290 295 300
Glu Glu Glu Gln Leu Ile Ser Gln Ala Ser Ser Lys Gln Ala Glu Glu
305 310 315 320
Ala Ser Gln Val Ser Lys Glu Ala Ser Gln Ala Thr Asn Gln Leu Ile
325 330 335
Gln Lys Leu Leu Asn Ile Ile Asp Asn Ile Asn Gln Ser Arg Asn Ser
340 345 350
Thr Ala Ser Gln Ile Ala Gly Asn Ile Arg Ala
355 360
<210>4
<211>332
<212>PRT
<213〉Shigella (Shigella)
<400>4
Met Asn Ile Thr Thr Leu Thr Asn Ser Ile Ser Thr Ser Ser Phe Ser
1 5 10 15
Pro Asn Asn Thr Asn Gly Ser Ser Thr Glu Thr Val Asn Ser Asp Ile
20 25 30
Lys Thr Thr Thr Ser Ser His Pro Val Ser Ser Leu Thr Met Leu Asn
35 40 45
Asp Thr Leu His Asn Ile Arg Thr Thr Asn Gln Ala Leu Lys Lys Asp
50 55 60
Leu Ser Gln Lys Thr Leu Thr Lys Thr Ser Leu Glu Glu Ile Ala Leu
65 70 75 80
His Ser Ser Gln Ile Ser Met Asp Val Asn Lys Ser Ala Gln Leu Leu
85 90 95
Asp Ile Leu Ser Lys Lys Glu Tyr Pro Ile Asn Lys Asp Ala Arg Glu
100 105 110
Leu Leu His Ser Ala Pro Lys Glu Ala Glu Leu Asp Gly Tyr Glu Met
115 120 125
Ile Ser His Arg Glu Leu Trp Asp Lys Ile Ala Lys Ser Ile Asn Asn
130 135 140
Ile Asn Glu Gln Tyr Leu Lys Val Tyr Glu His Ala Val Ser Ser Tyr
145 150 155 160
Thr Gln Met Tyr Gln Asp Phe Ser Ala Val Leu Ser Ser Leu Ala Gly
165 170 175
Trp Ile Ser Pro Gly Gly Asn Asp Gly Asn Ser Val Lys Leu Gln Val
180 185 190
Lys Ser Leu Lys Asp Glu Leu Thr Lys Leu Lys Glu Lys Tyr Lys Asp
195 200 205
Lys Pro Leu Tyr Pro Ala Asn Asn Thr Val Ser Lys Glu Gln Ala Asn
210 215 220
Lys Trp Leu Thr Glu Leu Gly Gly Thr Ile Gly Lys Val Ser Glu Lys
225 230 235 240
Asn Gly Gly Tyr Val Val Asn Ile Asn Met Thr Pro Ile Asp Asn Met
245 250 255
Leu Lys Ser Leu Asp Asn Leu Gly Gly Asn Gly Glu Val Val Leu Asp
260 265 270
Asn Ala Lys Tyr Gln Ala Trp Asn Ala Gly Phe Ser Ala Glu Asp Glu
275 280 285
Thr Met Lys Asn Asn Leu Gln Thr Leu Val Gln Lys Tyr Ser Asn Ala
290 295 300
Asn Ser Ile Phe Asp Asn Leu Val Lys Val Leu Ser Ser Thr Ile Ser
305 310 315 320
Ser Cys Thr Asp Thr Asp Lys Leu Phe Leu His Phe
325 330
<210>5
<211>1902
<212>DNA
<213〉Shigella (Shigella)
<400>5
atgcataatg taaataatac tcaagcgcca acattcttat ataaggcaac ttcaccatca 60
tcaacagaat acagcgagtt aaaaagcaaa atatccgata tccatagttc gcaaacttct 120
ctaaaaacac cagcatcagt gtctgaaaaa gaaaactttg caacgtcttt taatcagaaa 180
tgtcttgatt ttttattttc ttcctcaggg aaagaagatg tgttaagaag catttattcc 240
aactcaatga atgcgtatgc caaaagcgag attctcgaat tttcaaatgt tttgtactcc 300
ttagtacatc aaaatgatct taattttgaa aacgaaaagg gacttcaaaa aattgtcgca 360
cagtattcgg aactaattat aaaagataaa ttatcccaag attctgcctt tggaccatgg 420
tcggcaaaga ataagaaact ccatcaatta cgacaaaaca ttgagcacag acttgcacta 480
ttagcacaac aacacacatc tggtgaagct ttatcattgg gacaaaaact cctcaatact 540
gaagtatcat catttatcaa gaataatatt cttgctgaat taaagttaag taatgaaact 600
gtttcatctc tcaaactaga tgatttagtt gacgcacagg caaaacttgc ctttgatagt 660
ttgcgcaatc aacgtaaaaa tactattgat agtaaaggat ttggtatagg taaactgtca 720
agagacttaa atacagtagc cgtgtttcct gagctgttga gaaaagtcct taatgatatt 780
ttagaagata taaaagattc gcatcctatc caagatggcc tccctacacc tcccgaagat 840
atgccagatg gcggaccaac ccccggagcc aatgagaaaa catcccaacc tgtaattcac 900
tatcatataa ataatgataa tagaacttac gataatagag tttttgacaa cagagtatat 960
gacaatagct atcacgagaa cccagaaaat gatgcacagt ctcctacttc tcagacaaac 1020
gatctattat cccgtaacgg aaactcatta ctaaatccac aaagagcact agttcaaaaa 1080
gtaacttccg ttctaccaca ctctatatca gatgctgtcc agacatttgc aaataattca 1140
gctttagaaa aggttttcaa ccatactcca gataattcgg atggaatagg ttcagacctg 1200
ttaactacga gtagtcaaga aagatctaca aataactctc tttctcgggg acacaggcct 1260
ctgaacatac agaactcttc aaccaccccc cctctccacc cggaaggagt gacaagcagt 1320
aatgataact catcagatac aactaaaagt agcgcttctc tttctcatag agtagcttcg 1380
caaatcaata aattcaactc aaacactgat tcaaaagtac ttcagactga ttttttatca 1440
agaaatggag acacatattt aacacgggaa acgatatttg aagcttcaaa aaaagtaaca 1500
aactccctaa gtaatcttat atctctcatt ggaactaaat caggaacaca agaacgagag 1560
ttacaggaaa aatcaaagga cattacaaaa tccacaacag aacacagaat aaacaacaaa 1620
ttaaaagtta cagatgcaaa tacaataaac tacgtaacag aaaccaacgc agatacaatt 1680
gataaaaatc atgcgatcta tgaaaaggca aaagaagtat ctagcgccct cagcaaggta 1740
ttgtcaaaaa ttgacgatac ctctgcagaa ttacttacag atgatatatc tgatttaaaa 1800
aataacaatg atattacagc tgaaaacaat aatatatata aagcagcaaa agatgtaacc 1860
acttccctat caaaagtatt aaagaatatc aataaggatt aa 1902
<210>6
<211>1743
<212>DNA
<213〉Shigella (Shigella)
<400>6
atgcataatg taagcaccac aaccactggt ttgcctcttg ccaaaatatt ggcttccact 60
gagcttggag acaatactat ccaggctgca aatgatgcag ctaacaaatt attttctctt 120
acaattgctg atcttgctgc taacaaaaat attaatacaa ctaatgcaca ctcaacttcg 180
aatatattaa tccctgaact taaagcacca aagtcattaa atgcaagttc ccaactaacg 240
cttttaattg gaaaccttat tcaaatactt ggtgaaaaat ctttaactgc attaacaaat 300
aaaattactg cctggaagtc ccagcaacag gcaagacagc aaaaaaacct agaattctcc 360
gataaaatta atactcttct atctgaaact gaaggactaa ccagagacta tgaaaaacaa 420
attaataaac taaaaaacgc agattcaaaa ataaaagacc tagaaaataa aattaaccaa 480
attcaaacaa gattatccga actcgcccca gattcaccag aaaataaaaa attaagacgg 540
gaagaaatac aactcactat caaaaaagac gcagcagtta aagacaggac attgattgag 600
cagaaaactc tgtcaattca tagcaaactt acagataaat caatgcaact cgaaaaagaa 660
atagactctt tttctgcatt ttcaaacaca gcatctgctg aacagctatc aacccagcag 720
aaatcattaa ccggacttgc cagtgttact caattgatgg caacctttat tcaactagtt 780
ggaaaaaata atgaagaatc tttaaaaaat gatctggctc tattccagtc tctccaagaa 840
tcaagaaaaa ctgaaatgga gagaaaatct gatgagtatg ctgctgaagt acgtaaagca 900
gaagaactca acagagtaat gggttgtgtt gggaaaatac ttggggcact tttaactatc 960
gttagtgttg ttgcagcagc tttttctgga ggagcatctc tagcactggc agctgttggt 1020
ttagctctta tggttacgga tgctatagta caagcagcga ccggcaattc cttcatggaa 1080
caagccctga atccgatcat gaaagcagtc attgaaccct taatcaaact cctttcagat 1140
gcatttacaa aaatgctcga aggcttgggc gtcgactcga aaaaagccaa aatgattggc 1200
tctattctgg gggcaatcgc aggcgctctt gtcttggttg cagcagtcgt tctcgtagcc 1260
actgttggta aacaggcagc agcaaaactt gcagagaata ttggcaaaat aataggtaaa 1320
accctcacag accttatacc aaagtttctc aagaattttt cttctcaact ggacgattta 1380
atcactaatg ctgttgccag attaaataaa tttcttggtg cagcgggtga tgaagtaata 1440
tccaaacaaa ttatttccac ccatttaaac caagcagttt tattaggaga aagtgttaac 1500
tctgccacac aagcgggagg aaatgtcgct tctgctgttt tccaaaacaa cgcgtcgaaa 1560
aatctagcag acctgacatt atcgaaatat caagttgaac aactgtcaaa atacatcggt 1620
gacgcaatag aaaaattcgg ccaattgcag gaagtaattg cagagctgtt agcctcaatg 1680
tccaactctc aggctaatag aactgatgtt gcaaaagcaa ttttgcaaca aactactgct 1740
tga 1743
<210>7
<211>1092
<212>DNA
<213〉Shigella (Shigella)
<400>7
atggaaattc aaaacacaaa atcagccccg attttatata cagatatatc tacaaaacaa 60
actcaaagtt cttccgaaac acaaaaatca caaaattatc agcagttagc agcacatatt 120
ccacttaatg tcggtaaaaa tcccgtatta acaactacat taaatgatga tcaactttta 180
aagttatcag agcaggttca gcatgattca gaaatcattg ctcgccttac tgacaaaaag 240
atgaaagatc tttcagaaat gagtcacaca attaccccag agaacaccct ggatatttcc 300
agtctttctt ctaatgctgt ttctttaatt attagtgtag ccgttctact ttctgctctc 360
cgcactgcag aaactagatt gggctctcaa ttgtcattga ttgcgttcga tgctacaaaa 420
tcagctgcag agaacattgt tcggcaaggc ctagcagccc tatcatcaag cattactgga 480
gcggtcacac aagtaggtat aacgggtatc ggtgccaaaa aaacgcattc agggattagc 540
gaacaaaaag gagccttaag aaagaacctt gccactgctc aatctcttga aaaagagctt 600
gcaggttcta aattagggtt aaataaacaa atagatacaa atatcacctc accacaaact 660
aactctagca caaaaatttt aggtaaaaat aaactggcac cagataatat atccctgtca 720
actgaacata aaacttctct tagttctccc gatatttctt tgcaggataa aattgacacc 780
cagagaagag cttacgagct caataccctt tctgctcagc aaaaacaaaa cattggccgt 840
gcaacaatgg agacatcagc cgttgctggt aatatatcca catcaggagg gcgttataca 900
tctgctcttg aagaagaaga acaactaatc agtcaggcca gcagtaaaca agcagaggaa 960
gcatcccaag tatctaaaga agcatcccaa gcgacaaatc aattaataca aaaattattg 1020
aatataattg acaacatcaa ccaatcaagg aattctacag ccagtcagat tgctggtaac 1080
attcgagctt aa 1092
<210>8
<211>998
<212>DNA
<213〉Shigella (Shigella)
<400>8
atgaatataa caactctgac taatagtatt tccacctcat cattcagccc aaacaatacc 60
aacggttcat caaccgaaac agttaattct gatataaaaa caacgaccag ttctcatcct 120
gtaagttccc ttactatgct caacgacacc cttcataata tcagaacaac aaatcaggca 180
ttaaagaaag atctctcaca aaaaacgttg actaaaacat cgctagaaga aatagcatta 240
cattcatctc agattagcat ggatgtaaac aaatccgctc aactattgga tattctttcc 300
aagaaagaat atccaattaa taaagacgca agagaattat tacattcagc cccgaaagaa 360
gccgagcttg atggatatga aatgatatct cacagagaac tgtgggataa aattgcaaag 420
tcaatcaata atattaatga acagtatctg aaagtatatg aacatgccgt tagttcatat 480
actcaaatgt atcaagattt tagcgctgtt ctttccagtc ttgccggctg gatctctccc 540
ggaggtaacg acggaaactc cgtgaaatta caagtcaaat cgcttaaaga cgaattgaca 600
aagctcaagg aaaaatataa gataaaccgc tatatccagc aaataatact gttagtaagg 660
aacaagcaaa taaatggctt acagaattag gtggaacaat cggcaaggta tctgaaaaaa 720
acgggggata tgttgtcaat ataaacatga ccccaataga caatatgtta aaaagcttag 780
ataatctagg tggaaatggc gaggttgtgc tagataatgc aaaatatcag gcatggaatg 840
ccggattctc tgccgaagat gaaacaatga aaaataatct tcaaacttta gttcaaaaat 900
acagtaatgc caatagtatt tttgataatt tagtaaaggt tttgagtagt acaataagct 960
catgtacaga tacagataaa ctttttctcc atttctga 998

Claims (10)

1, a kind of dysentery multivalent genetic engineering vaccine, its activeconstituents are both to have expressed invasin protein antigen I paA, IpaB, and IpaC and IpaD express the dysentery multivalent genetic engineering vaccine strain of the two valency LPS-0 polysaccharide antigens of Fu Shi and Song Nei Shi again.
2, vaccine according to claim 1 is characterized in that: the production substratum of described dysentery multivalent genetic engineering vaccine is that pH is Hou Shi substratum or the LB substratum of 6.5-7.6.
3, vaccine according to claim 2 is characterized in that: the pH of described production substratum is 7.2-7.5.
4, according to claim 1 or 2 or 3 described vaccines, it is characterized in that: the formulation of described dysentery multivalent genetic engineering vaccine is capsule oral formulation or form of nose drops.
5, vaccine according to claim 4 is characterized in that: the dysentery multivalent genetic engineering vaccine of described formulation adopts lyophilization to be prepared.
6, vaccine according to claim 5, it is characterized in that: the lyophilized vaccine that is adopted in the dysentery multivalent genetic engineering vaccine process of the described formulation of preparation is 0.5% gelatin that contains of pH7.0-7.6, the phosphoric acid buffer of 5% sucrose, 0.2% vitamins C, 0.1% thiaminogen, 0.1% skim-milk; Described percentage composition is a quality quality percentage composition.
7, a kind of method for preparing the described dysentery multivalent genetic engineering vaccine strain of claim 1 may further comprise the steps:
1) will contain invasin protein IpaA, IpaB, the I of IpaC and IpaD gene plasmid mutually transfer among the shigella flexneri 2a type II, obtain containing the reorganization shigella flexneri 2a type II of described I phase plasmid;
2) will contain aroD genetically deficient among the reorganization shigella flexneri 2a type II of described I phase plasmid, both expressed invasin protein antigen I paA, IpaB, IpaC and IpaD, expressed the dysentery multivalent genetic engineering vaccine strain of the two valency LPS-O polysaccharide antigens of Fu Shi and Song Nei Shi again.
8, method according to claim 7 is characterized in that: the described invasin protein IpaA that contains, IpaB, the I of IpaC and IpaD gene plasmid mutually come from Song Nei Shi dysentery bacillus strain 48025-11 or Song Nei Shi dysentery bacterial strain S63.
9, method according to claim 7 is characterized in that: the described invasin protein IpaA that contains, IpaB, the I of IpaC and IpaD gene plasmid mutually transfer among the shigella flexneri 2a type II by luring kinoplaszm grain R386; The described kinoplaszm grain R386 that lures comes from E.coli.
10, according to claim 7 or 8 or 9 described methods, it is characterized in that: described shigella flexneri 2a type II is a shigella flexneri 2a type II T32 bacterial strain.
CNA2005100898519A 2005-08-09 2005-08-09 Dysentery multivalent genetic engineering vaccine and preparation method thereof Pending CN1912106A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2005100898519A CN1912106A (en) 2005-08-09 2005-08-09 Dysentery multivalent genetic engineering vaccine and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2005100898519A CN1912106A (en) 2005-08-09 2005-08-09 Dysentery multivalent genetic engineering vaccine and preparation method thereof

Publications (1)

Publication Number Publication Date
CN1912106A true CN1912106A (en) 2007-02-14

Family

ID=37721169

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005100898519A Pending CN1912106A (en) 2005-08-09 2005-08-09 Dysentery multivalent genetic engineering vaccine and preparation method thereof

Country Status (1)

Country Link
CN (1) CN1912106A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076610A1 (en) * 2019-10-14 2021-04-22 The Board Of Trustees Of The University Of Illinois Shigella multi-epitope fusion antigen proteins and methods of use
CN114025789A (en) * 2019-04-02 2022-02-08 Vaxcyte公司 Optimized cell-free synthesis of invasive plasmid antigen B and related compositions and methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114025789A (en) * 2019-04-02 2022-02-08 Vaxcyte公司 Optimized cell-free synthesis of invasive plasmid antigen B and related compositions and methods of use
WO2021076610A1 (en) * 2019-10-14 2021-04-22 The Board Of Trustees Of The University Of Illinois Shigella multi-epitope fusion antigen proteins and methods of use

Similar Documents

Publication Publication Date Title
CN1197618C (en) Mutant cholera holotoxin as an adjuvant
CN1201818C (en) Vaccine
CN1946420A (en) Immunising against meningococcal serogroup y using proteins
CN101048175A (en) Immunogenic bacterial vesicles with outer membrane proteins
CN1679929A (en) Streptococcal c5a peptidase vaccine
CN1809380A (en) Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CN86103835A (en) Oral vaccine
CN1849388A (en) Lactic acid bacteria having mucosal immunopotentiation effect
CN1147769A (en) Para-influenza virus-containing vaccines for preventing porcine reproductive and respiratory syndrome
CN1198932C (en) Streptococcus pneumoniae antigens
CN1298848C (en) Analog of haemophilus Hin47 with reduced protease activity
CN1798844A (en) Cell surface expression vector of SARS virus antigen and microorganisms transformed thereby
CN101033468A (en) Helicobacter pylori urease B subunit B cell antigen epitope polypeptide, identification method and application
CN1063416A (en) Avirulent microbes and uses thereof: Salmonella typhi
CN1901924A (en) Method for inhibiting bacterial colonisation
CN1899610A (en) Pyloric spiral bacillus antigen recombinant vaccine
CN1807452A (en) Helicobacter Pylori urease B subunit Th epitope peptide, its coding DNA, vaccine and uses
CN1228450C (en) Antigenic preparations
CN1245512C (en) Vaccines containing recombinant pilin against i cneisseria gonorrhoeae (or i cneisseria meningitidis)
CN1912106A (en) Dysentery multivalent genetic engineering vaccine and preparation method thereof
CN1906210A (en) Surface-located campylobacter jejuni polypeptides
CN1780640A (en) Attenuated strains of vibrio cholerae and lyophilised vaccines containing same
CN1629188A (en) Specific antigen of Japanese blood fluke and its use
CN1768079A (en) Polypeptide
CN1736479A (en) Prevention, treatment and detection of pig progressive atrophic rhinitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070214